Expand The

Horizon

Each stem cell transplant is a personalized journey. No paths are exactly alike, but the outlook is the same: hope on the horizon.

Advances in cell therapy will redefine expectations of who can make the journey, and what the path forward will reveal.

What advances could extend the promise of transplant to more patients in need?

WHAT PERSPECTIVES COULD BE REVEALED THAT WILL:

Open the field

with more transplants for more waiting patients.

smooth the path

with optimized solutions and better outcomes.

clear the way

with a straightforward experience for patients.

Let’s expand the horizon.

THE LANDSCAPE TODAY
THE LANDSCAPE TODAY

Cell therapy has always been a forward-looking field for those who seek paths for their patients beyond conventional options.1

Over 18,000 new patients with hematologic malignancies are considered for transplant each year, initiating a journey of hope for a personal cure.2

The innovations that make this possible are scientific, organizational, and social; new medicines, evidence-driven practices, and the essential work of organizations such as the National Marrow Donor Program (NMDP) and the American Society for Transplantation and Cellular Therapy (ASTCT) all help illuminate a brighter path for patients.

WHICH DO YOU SEE AS THE TOP ADVANCE OF THE LAST FEW DECADES?

Advent of unrelated
donor registries
Introduction of umbilical cord blood as a viable graft source
Process of peripheral blood stem cell collection
Improvement of post-transplant treatments for haploidentical recipients
Emergence of reduced intensity conditioning regimens
Development
of novel pharmaceutical agents as new treatment options
Registries were established over 30 years ago, introducing a monumental shift that increased access to new donor sources.3

WHICH DO YOU SEE AS THE TOP ADVANCE OF THE LAST FEW DECADES?

Advent of unrelated
donor registries
Advent of unrelated
donor registries
Introduction of umbilical cord blood as a viable graft source
Introduction of umbilical cord blood as a viable graft source
Process of peripheral blood stem cell collection
Process of peripheral blood stem cell collection
Improvement of post-transplant treatments for haploidentical recipients
Improvement of post-transplant treatments for haploidentical recipients
Emergence of reduced intensity conditioning regimens
Emergence of reduced intensity conditioning regimens
Development
of novel pharmaceutical agents as new treatment options
Development
of novel pharmaceutical agents as new treatment options
Registries were established over 30 years ago, introducing a monumental shift that increased access to new donor sources.3
CHALLENGING PATHS
CHALLENGING PATHS

Despite our achievements as a community,
the path to transplant remains challenging.

Despite our achievements as a community,
the path to transplant remains challenging.

Every year, more than 5000 eligible patients do not receive transplant.9

Graft sources vary widely, with complex dimensions that require calculated decisions.

Patients may experience ANXIETY throughout the process.10

SELECT TO FIND OUT MORE ABOUT:

Eligible but Untreated
Historically
Excluded
Advanced
Donor Age
Transplant Timeline and Variances
Logistical and
Financial Barriers
Progress Against Transplant Goals
Over 5,000 patients diagnosed with a hematologic malignancy in the U.S. each year are eligible for curative allogeneic transplant, but do not receive one.9

SELECT TO FIND OUT MORE ABOUT:

Eligible but Untreated
Over 5,000 patients diagnosed with a hematologic malignancy in the U.S. each year are eligible for curative allogeneic transplant, but do not receive one.9
SEEKING CHANGE
SEEKING CHANGE

WHERE CAN WE LOOK TO CREATE THE GREATEST CHANGE IN THE TREATMENT LANDSCAPE?

WHERE CAN WE LOOK TO CREATE THE GREATEST CHANGE IN THE TREATMENT LANDSCAPE?

The essential foundation for every transplant is the donor source – and its quality and cellular composition may determine the short- and long-term effects.17

So much depends on these selected cells: to restore and renew.

For decades, transplant has relied mainly on adult donors, related or unrelated. But today, as new vistas in cell engineering emerge, innovations will lead us to the next step in expectations for donor sources and engraftment.

CELL-BASED THERAPEUTIC STRATEGIES

Cellular engineering, principally the control and regulation of cell proliferation, differentiation, and function, is vital to the success of cell‐based therapeutic applications and technologies.

Source Identification

Preference for graft source varies across institutions with Matched Related Donors being the gold standard and transplanters weighing advantages and compromises of other available sources.16

When multiple graft sources are available, transplanters select for optimized cellularity and cellular compositions, particularly with regard to CD34+ cell counts and T cells, as they may play a major role in transplant outcomes.17

Selection / Depletion

Strategies, such as the use of cytokines and the selective depletion of certain cellular types, may present a promising approach to preserving GvL effects while reducing GvHD.18

EXPANSION

Ex vivo expansion of stem cells may help to alleviate the issue of material shortage for transplantation purposes. Refinement of current protocols, development of optimal conditions for expansion, and preservation of cellular functionality and phenotype during expansion may lead to critical advancements in cellular therapy.19

Enrichment

Optimization of procedures to mitigate the risk of GvHD, such as the enrichment or immunomodulation of certain immune cells, is vital to obtain better outcomes.20

MODIFICATION

In order to lower the risk of severe GvHD, in vitro cell engineering methods to enhance safety, decrease alloreactivity, and strengthen protective anti-pathogen and anti-leukemic responses following allogeneic HSCT are pertinent to consider.20

Prepare / Deliver

Standardized processes to maximize cell product preservation and ensure timely and reliable delivery before infusion are essential to optimize day of transplant.